Liver Transplantation Center, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.
Division of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, MD, USA.
Clin Interv Aging. 2021 Sep 13;16:1633-1649. doi: 10.2147/CIA.S295524. eCollection 2021.
Non-alcoholic fatty liver disease (NAFLD) is an increasingly prevalent disease globally. Current estimates are that 24% of the adult population, thus, one billion individuals worldwide, are affected. Interestingly, the prevalence of fatty liver seems to peak between 40─50 years of age in males and 60─69 years in females, often slightly decreasing in older (>70 years) cohorts. Furthermore, several risk factors for NAFLD development, such as hypertension, diabetes, hyperlipidemia, and obesity are higher in older adults. The diagnosis and management strategies in older adults are sometimes challenging, and certain age-specific factors have to be taken into account by healthcare professionals. In this review, we provide an overview of considerations relevant to the management and diagnosis of NAFLD in older adults (age >65 years) and discuss the types of pharmacological interventions available for the management of non-alcoholic steatohepatitis (NASH) in the aging population.
非酒精性脂肪性肝病（NAFLD）是一种在全球范围内日益流行的疾病。目前的估计是，全球有 24%的成年人，即 10 亿人受到影响。有趣的是，脂肪肝的患病率似乎在男性中 40─50 岁和女性中 60─69 岁之间达到峰值，在年龄较大（>70 岁）的人群中略有下降。此外，NAFLD 发展的一些危险因素，如高血压、糖尿病、高血脂和肥胖，在老年人中更高。老年人的诊断和管理策略有时具有挑战性，医疗保健专业人员必须考虑某些特定于年龄的因素。在这篇综述中，我们概述了与老年人（年龄>65 岁）NAFLD 管理和诊断相关的注意事项，并讨论了适用于老龄化人群非酒精性脂肪性肝炎（NASH）管理的药物干预类型。
